Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Tim Y-T. Lu"'
Publikováno v:
Neuroimmunology Reports. 3:100159
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5f649cbecd408c12f251847466c818b2
https://doi.org/10.1016/j.nerep.2022.100159
https://doi.org/10.1016/j.nerep.2022.100159
Autor:
Manuela F. Fontanillo, José M. Pego-Reigosa, Tim Y.-T. Lu, Víctor del Campo-Pérez, David A. Isenberg, Anisur Rahman
Publikováno v:
Rheumatology. 49:691-696
Objective. Lipid abnormalities contribute to the increased risk of premature atherosclerosis in patients with SLE. This study was undertaken to investigate changes in lipid profile after B-cell depletion therapy (BCDT) in patients with active SLE who
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e4ca7f79a036a670e27e2c1e26fee6cb
https://doi.org/10.1093/rheumatology/kep446
https://doi.org/10.1093/rheumatology/kep446
Autor:
David A. Isenberg, Iva Gunnarsson, Ana Filipa Mourão, Thorunn Jonsdottir, Tim Y.-T. Lu, Ronald F van Vollenhoven
Publikováno v:
Rheumatology. 49:1502-1504
Objective. To compare the clinical results after treatment with B-cell depleting therapy in patients with membranous (WHO Class V) vs proliferative (WHO Class III or IV) lupus nephritis (LN). Methods. Data were compiled from two European centres on a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::13d4eb02a4080ed00383cf098b3b1c25
https://doi.org/10.1093/rheumatology/keq055
https://doi.org/10.1093/rheumatology/keq055
Autor:
Tabitha Turner-Stokes, Anisur Rahman, Ian Giles, M. Ehrenstein, David A. Isenberg, Tim Y.-T. Lu
Publikováno v:
Scopus-Elsevier
Since 2000, we have given B-cell depletion therapy (BCDT) with rituximab to 76 patients with active SLE refractory to standard immunosuppression. Twenty-four of these patients have now received repeated cycles of BCDT. The aims of the study were to:
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::34713b2aa802a9517d76662262dd1366
https://pubmed.ncbi.nlm.nih.gov/22491718
https://pubmed.ncbi.nlm.nih.gov/22491718
Autor:
Tamar B. Rubinstein, Noa Schwartz, Julie Schwartzman, Elena Weinstein, Tim Y.-T. Lu, Benjamin Levine, Chaim Putterman, Anisur Rahman, Milena Pitashny, David A. Isenberg, José M. Pego-Reigosa
Publikováno v:
Scopus-Elsevier
Objectives. Clinical and laboratory markers in current use have limited specificity and sensitivity for predicting the development of renal disease in lupus patients. In this longitudinal study, we investigated whether urinary neutrophil gelatinase-a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46c10ba8fb7b888cadb7189514c815c6
https://europepmc.org/articles/PMC2853702/
https://europepmc.org/articles/PMC2853702/
Autor:
Tim Y.-T. Lu, Geraldine Cambridge, David A. Isenberg, Maria J. Leandro, Michael R. Ehrenstein, Jonathan C. W. Edwards, Kristine P Ng
Publikováno v:
Arthritis and rheumatism. 61(4)
Objective To describe the 6-month clinical outcome and the long-term safety profile of B cell depletion therapy (BCDT) in 50 patients with active systemic lupus erythematosus (SLE), who were nonresponsive or poorly responsive to conventional immunosu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d50e51935c5174bfca9a76e0309746b
https://pubmed.ncbi.nlm.nih.gov/19714598
https://pubmed.ncbi.nlm.nih.gov/19714598